The ABLE-32 Study: Nadofaragene Firadenovec for Intermediate-Risk NMIBC
8:51
HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer
6:28
Overcoming the BCG Shortage With TARA-002 for High-Grade NMIBC
11:57
RCC Prognostics and Diagnostics Highlights from SUO 2024
12:02
AI-Powered Biomarkers and Precision Medicine in High-Risk NMIBC
8:22
BOND-003 With Dr. Mark D. Tyson: Cretostimogene for BCG-Unresponsive Bladder Cancer
3:19
Live long and PROSPER: enzalutamide for nmCRPC
5:08
STRATA Study: The Role of Cxbladder Triage in Reducing Cystoscopy Burden
6:45